https://www.selleckchem.com/products/Rolipram.html
86 (0.80-0.93)], and no effect in at-risk patients without history of cardiovascular events [GLP1-RA 0.94 (0.82-1.07); SGLT-2i 1.00 (0.87-1.16)]. We observed a trend toward larger treatment benefits with SGLT-2i among patients with chronic kidney disease [0.82 (0.69-0.97)], and patients with uncontrolled diabetes for both GLP1-RA or SGLT-2i [GLP1-RA 0.82 (0.71-0.95); SGLT-2i 0.84 (0.75-0.95)]. Uncontrolled hypertension, obesity, gender, age and race did not appear to modify the effect of these drugs. In this exploratory analysis, histo
Like
Comment
Share
